In Brief A new venture that aims to combine longevity research with artificial intelligence is in the works, thanks to funding from British billionaire Jim Mellon. The new company will focus on finding faster ways to develop drugs that fight aging. A Long and Healthy Life
It turns out, writing about your investment ideas before actually putting money into them is a nifty strategy for ensuring success. It’s proven to work for British billionaire Jim Mellon, anyways. He hopes to continue the trend with his latest book, Juvenescence: Investing in the Age of Longevity, by using it as the jumping off point for a new biotech company with a focus on putting an end to aging.
Juvenescence Limited is a joint venture between Mellon and longevity researchers Gregory Bailey and Declan Doogan. Under that parent umbrella is Juvenescence AI, a joint venture with Alexander Zhavoronkov, CEO of Baltimore-based Insilico Medicine, Inc., a drug
How to Automate Video Content Marketing in Under 1 Hour
5 Easy Video Lessons +
Bonus Free Toolkit